Stroke Unit Versus General Medical Wards I

Completed

Phase N/A Results

Trial Description

To test the hypothesis that stroke units with a short hospitalization time would be effective for increased survival among unselected stroke patients at least 1 year after the stroke.

Interventions

Trial Design

Quasi-randomized (randomization based on date of birth in month), controlled trial of 802 patients at a single center.

Patient Involvement

Patients were randomized to receive care in a stroke unit (SU) or in a general medical ward (GMW). Medical treatment in the SU followed current practice guidelines for the management of patients with acute stroke which included immediate administration of aspirin if ischemic stroke was suspected after clinical and CT evaluation, mobilization of all patients as early as possible, administration of parenteral isoosmolar fluid for the first 24 hours, treatment of hyperglycemia with insulin, treatment of fever with antipyretics, administration of low-molecular-weight heparin for immobilized patients, anticoagulation if cardioembolic stroke suspected, and physiotherapy using Bobath technique. In the SU, treatment was multidisciplinary, coordinated and included patients' relatives. Patients randomized to GMW received care in one of five wards depending on capacity. These patients were given traditional, good medical treatment without special efforts or standardized effort toward this patient group. Care in the GMW differed from the SU in that mobilization was discouraged until hemorrhage was excluded by CT scan and there was no routine use of antipyretics or parenteral isoosmolar fluids. After acute medical treatment, stabilization and early rehabilitation for an average of one week, patients in both groups were discharged either home, to nursing homes, to community-based long-term rehabilitation, or to hospital-based long-term rehabilitation. Patients were followed until death or the end of observation, 18 months after stroke.

Outcomes

Type Measure Time Frame Safety Issue
No outcomes associated with this trial.